Clinical Trials Directory

Trials / Unknown

UnknownNCT01705457

Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis

Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Tehran University of Medical Sciences · Academic / Other
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate)on retinoic acid receptor and retinoic x receptor expression.

Detailed description

Multiple Sclerosis (MS) is a chronic inflammatory disease where Th1 like responses from myelin-specific CD4+ T cells, as secretion of pro-inflammatory IFNγ, are believed to play a major role in the pathogenesis. The myelin-specific T cells that mediate tissue destruction in MS are believed to become activated outside the central nervous system (CNS) in lymphoid tissue and when they cross the blood brain barrier they will re-encounter their antigen. Immune deviation is the redirection of the immune response from most often Th1 like responses to Th2 like responses, even though the opposite can also occur. Vitamin A or Vitamin A-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. High level dietary vitamin A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine production. Retinoic acid(RA) inhibits IL12 production in activated macrophages, and RA pretreatment of macrophages reduces IFNγ production and increases IL4 production in antigen primed CD4 T cells. Supplemental treatment with vitamin A or RA decreases IFNγ and increases IL5, IL10, and IL4 production by increase of retinoic acid receptor and retinoic x receptor . Record Verification Date: August 2011

Conditions

Interventions

TypeNameDescription
DRUGDietary Supplement: vitamin A25000 IU/day vitamin A for 6 months 1 Cap/Day 1 cap placebo/day for 6 month
DRUGplacebo

Timeline

Start date
2010-02-01
Primary completion
2013-02-01
Completion
2013-08-01
First posted
2012-10-12
Last updated
2012-10-12

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT01705457. Inclusion in this directory is not an endorsement.